The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor Dave Meier discuss topics across the investing world.

Dave and John consider the prospects of Pfizer over the next five years. They both find its dividend pretty attractive, but they also wonder about its long-term potential. The video concludes with Dave's call on the stock.

Dave Meier and John Reeves have no positions in the stocks mentioned above. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services recommend Pfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.